Leukemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:


==Classification==
==Classification==
Leukemia can be classified as follows:




==Differentiating Leukemia from other Diseases==
==Differentiating Leukemia from other Diseases==
===Differenting Chronic lymphocytic leukemia from other Diseases===
Leukemia must be differentiated from various diseases that cause [[weight loss]],  [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], prolymphocytic leukaemia, [[follicular lymphoma]], and [[mantle cell lymphoma]]. Based on the expression of cell surface markers, the table below differentiates different types of leukemia from other diseases that cause similar clinical presentations:<ref name="H">Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
* Leukemia must be differentiated from various diseases that cause [[weight loss]],  [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], prolymphocytic leukaemia, [[follicular lymphoma]], and [[mantle cell lymphoma]].
 
* Based on the expression of cell surface markers, the table below differentiates different types of leukemia from other diseases that cause similar clinical presentations:<ref name="H">Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
<br>
<br>
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
|valign=top|
| valign="top" |
|+
|+
! style="background: #4479BA; width: 600px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
! style="background: #4479BA; width: 600px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
Line 39: Line 40:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Chronic lymphocytic leukemia'''
'''Chronic lymphocytic leukemia'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Weakly positive'''
'''Weakly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive/Negative'''
'''Positive/Negative'''


Line 56: Line 57:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Prolymphocytic leukemia'''
'''Prolymphocytic leukemia'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''


Line 73: Line 74:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Hairy cell leukemia'''
'''Hairy cell leukemia'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive/Negative'''
'''Positive/Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''


Line 90: Line 91:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Mantle cell lymphoma'''
'''Mantle cell lymphoma'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''


Line 107: Line 108:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
'''Follicular lymphoma'''
'''Follicular lymphoma'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''  
'''Negative'''  
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Positive'''
'''Positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Strongly positive'''
'''Strongly positive'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
'''Negative'''
'''Negative'''
|}
|}
<br>
<br>
* Chronic lymphocytic leukemia must also be differentiated from other causes of fever, hepatosplenomegaly, and lymph node swelling such as:<ref name="wiki">Chronic Lymphocytic Leukimea. Wikipedia (2015) https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia Accessed on October ,12 2015</ref>
:* [[Splenic marginal zone lymphoma]]
:* Nodal marginal zone [[lymphoma]]
:* [[Lymphoplasmacytic lymphoma]]
:* [[Sézary syndrome]]
:* Smoldering [[adult T cell leukemia]]


Acute myeloid leukemia should be differentiated from the following hematological disorders:
{| class="wikitable"
!Disease
!Differential Diagnosis
|-
|AML
|
* [[Acute lymphoblastic leukemia]]  
* [[Acute lymphoblastic leukemia]]  
* [[Chronic myelogenous leukemia]]  
* [[Chronic myelogenous leukemia]]  
Line 136: Line 136:
* [[Myelodysplastic syndrome]]
* [[Myelodysplastic syndrome]]
* [[Myeloproliferative disorders]]
* [[Myeloproliferative disorders]]
|-
|ALL
|
* [[Acute myelogenous leukemia]]
* [[Hairy cell leukemia]]
* [[Malignant lymphoma]]
|-
|CML
|
* [[Leukemoid reaction]]
* [[Chronic neutrophilic leukemia]]
* [[Acute myeloid leukemia]]
* [[Thrombocytosis]]
|-
|CLL
|
* [[Splenic marginal zone lymphoma]]
* Nodal marginal zone [[lymphoma]]
* [[Lymphoplasmacytic lymphoma]]
* [[Sézary syndrome]]
* Smoldering [[adult T cell leukemia]]
|-
|HCL
|
* [[Mantle cell lymphoma|Mantle cell]] and [[follicular lymphoma]]
* [[Chronic lymphocytic leukemia|CLL]]
* [[Prolymphocytic leukemia]]
On basis of [[fever]], [[splenomegaly]], and [[fatigue]]
* [[Aplastic anemia]]
* [[Myelodysplastic syndrome]]
* [[Splenic marginal zone lymphoma]]
* [[B-cell prolymphocytic leukemia]]
* [[Idiopathic myelofibrosis]]
|}


==Epidemiology and Demographics==
==Epidemiology and Demographics==
Line 158: Line 193:
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Acute lymphoblastic leukemia'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | '''Chronic lymphocytic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Acute myeloid leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Chronic myeloid leukemia'''
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Acute lymphoblastic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | '''Chronic lymphocytic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Acute myeloid leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Chronic myeloid leukemia'''
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All ages'''||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 1.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |4.4|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |3.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.7
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''All ages'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 1.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |4.4|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |3.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |1.7
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''<65''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.7 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.4||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 1.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.9
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''<65''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |1.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |1.4|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 1.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |0.9
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''≥65''' ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 1.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |25.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |17.5||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |6.8
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''≥65''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 1.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |25.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |17.5|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |6.8
|}
|}


Line 190: Line 225:
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic'''  
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''All Races''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Hispanic'''  
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted [[prevalence]]'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |75.3 per 100,000||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |83.5 per 100,000||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |45.9 per 100,000||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |41.2 per 100,000||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |57.1 per 100,000
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Age-adjusted [[prevalence]]'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |75.3 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |83.5 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |45.9 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |41.2 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |57.1 per 100,000
|}
|}


Line 212: Line 247:
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Acute lymphoblastic leukemia'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | '''Chronic lymphocytic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Acute myeloid leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Chronic myeloid leukemia'''
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Acute lymphoblastic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | '''Chronic lymphocytic leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Acute myeloid leukemia'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Chronic myeloid leukemia'''
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''5-year survival'''||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 70% || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |83.5%|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |25.4% || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |59.9%
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''5-year survival'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 70% || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |83.5%|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |25.4% || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |59.9%
|}
|}



Revision as of 14:39, 21 July 2017

Template:DiseaseDisorder infobox

Leukemia Microchapters

Home

Patient Information

Overview

Classification

AML
CML
ALL
CLL

Differentiating Leukemia from other Diseases

Epidemiology and Demographics

Prognosis

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Leukaemia

Overview

Leukemia (Greek leukos, “white”; haima, “blood”) is a cancer of the blood or bone marrow and is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes). It is part of the broad group of diseases called hematological neoplasms.

Classification

Leukemia can be classified as follows:


Differentiating Leukemia from other Diseases

Leukemia must be differentiated from various diseases that cause weight loss, night sweats, hepatosplenomegaly, and palpable lymph nodes, such as hairy cell leukaemia, prolymphocytic leukaemia, follicular lymphoma, and mantle cell lymphoma. Based on the expression of cell surface markers, the table below differentiates different types of leukemia from other diseases that cause similar clinical presentations:[1]


Differential Diagnosis Surface Immunoglobulin CD5 CD22/FMC7 CD23 CD79b CD103

Chronic lymphocytic leukemia

Weakly positive

Positive

Negative

Positive

Negative

Positive/Negative

Prolymphocytic leukemia

Strongly positive

Negative

Positive

Negative

Positive

Negative

Hairy cell leukemia

Strongly positive

Negative

Positive

Negative

Positive/Negative

Positive

Mantle cell lymphoma

Positive

Positive

Strongly positive

Negative

Strongly positive

Negative

Follicular lymphoma

Strongly positive

Negative

Positive

Negative

Strongly positive

Negative


Disease Differential Diagnosis
AML
ALL
CML
CLL
HCL

On basis of fever, splenomegaly, and fatigue

Epidemiology and Demographics

Prevalence

  • In the United States, the age-adjusted prevalence of leukemia is 75.3 per 100,000 in 2011.[2]

Incidence

  • The delay-adjusted incidence of leukemia in 2011 was estimated to be 15.48 per 100,000 persons in the United States.[2]
  • In 2011, the age-adjusted incidence of leukemia was 13.66 per 100,000 persons in the United States.[2]

Age

  • The overall age-adjusted incidence of leukemia in the United States between 2007 and 2011 is 13 per 100,000, the age-adjusted incidence of leukemia by age category is:[2]
    • Under 65 years: 6.5 per 100,000
    • 65 and over: 57.9 per 100,000
  • Shown below is a table depicting the overall age-adjusted incidence of leukemia per 100,000 individuals by age in the United States between 2007 and 2011 for the different types of leukemia.[2]
Acute lymphoblastic leukemia Chronic lymphocytic leukemia Acute myeloid leukemia Chronic myeloid leukemia
All ages 1.7 4.4 3.8 1.7
<65 1.7 1.4 1.8 0.9
≥65 1.6 25.2 17.5 6.8

Gender

  • In the United States, the age-adjusted prevalence of leukemia by gender in 2011 is:[2]
    • In males: 92.7 per 100,000
    • In females: 60.7 per 100,000
  • In the United States, the delay-adjusted incidence of leukemia by gender in 2011 is:[2]
    • In males: 19.93 per 100,000 persons
    • In females: 11.89 per 100,000 persons
  • In the United States, the age-adjusted incidence of leukemia by gender on 2011 is:[2]
    • In males: 17.58 per 100,000 persons
    • In females: 10.49 per 100,000 persons
  • Shown below is an image depicting the delay-adjusted incidence and observed incidence of leukemia by gender and race in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[2]

Delay-adjusted incidence and observed incidence of leukemia by gender and race in the United States between 1975 and 2011

Race

  • Shown below is a table depicting the age-adjusted prevalence of leukemia by race in 2011 in the United States.[2]
All Races White Black Asian/Pacific Islander Hispanic
Age-adjusted prevalence 75.3 per 100,000 83.5 per 100,000 45.9 per 100,000 41.2 per 100,000 57.1 per 100,000
  • Shown below is an image depicting the incidence of leukemia by race in the United States between 1975 and 2011.[2]

Incidence of leukemia by race in the United States between 1975 and 2011

API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native

Prognosis

5-Year Survival

  • Between 2004 and 2010, the 5-year relative survival of patients with leukemia was 60.3%.[2]
  • When stratified by age, the 5-year relative survival of patients with leukemia was 68.5% and 44.1% for patients <65 and ≥ 65 years of age respectively.[2]
  • Shown below is a table depicting the 5-year relative survival of patients by the type of leukemia in the United States between 2004 and 2010.
Acute lymphoblastic leukemia Chronic lymphocytic leukemia Acute myeloid leukemia Chronic myeloid leukemia
5-year survival 70% 83.5% 25.4% 59.9%

References

  1. Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Template:Blood


Template:WikiDoc Sources